|Day Low/High||0.73 / 0.79|
|52 Wk Low/High||0.60 / 2.11|
Biotech stock watchdog Adam Feuerstein looks back at the best and worst of Mailbag 2009.
Pixantrone will be reviewed by an FDA advisory panel on Feb. 10.
A quick and dirty guide to the expected regulatory news from the FDA through June 2010.
Biotech columnist Adam Feuerstein answers reader email about Cell Therapeutics and other stocks.
CEO spotted in New York with bankers in tow, looking at his wallet.
Federal appeals court: Seattle biotech can pursue $23 million claim against former consultant
Risky late-game call puts Poniard in a deep financial hole.
Is it the drug or the gel that worked best in a phase II study?
'Retention' bonus awarded to CEO Jim Bianco, his management team and directors.
Several small-cap stocks were moving on above-average volume during Thursday's session.
More work needs to be done before penciling in approval.
Cell Therapeutics says it asked EU regulators to grant orphan drug status to pixantrone
Adam Feuerstein fields questions on Myriad Pharma, Hemispherx, Cell Therapeutics, Gilead and more.
Cell Therapeutics has withdrawn its European approval application for the lung cancer drug Opaxio. But you wouldn't quite get that from the company's statement Monday.
Adam details his whereabouts on Sept. 9 and tackles readers' questions about Cyclacel, Epicept and a few more familiar names.
On a strong day for the sector, the buyout rumors are buzzing
FDA doesn't raise new safety issues for Auxilium's hand treatment
Jim Bianco unloads 30% of holdings days after investor meeting.
Investors waiting for government to buy emergency stockpile of peramivir
Uncertainty over Zevalin's relaunch likely weighing on stock price
Negative results announced from two phase III studies in graft-versus-host-disease
Spectrum Pharma says FDA approved Zevalin as first-line treatment for non-Hodgkin's lymphoma
The FDA says Spectrum can market Zevalin as a first-line consolidation therapy for NHL patients.
Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.
FDA review status of Cell Therapeutics' key cancer drug Pixantrone is unclear.
Cell Therapeutics says FDA will review experimental drug for cancer
Outrage on Citigroup and the Fed and Adam Feuerstein's biotech calendar.
Citigroup retains the top spot in TheStreet's Stock Search list today, as it seemingly has since the dawn of time. New entries to the list include ValeS.A., AIG, Rentech and Ford.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.